0082N0 — Kanaph Therapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩599bn
- KR₩590bn
- KR₩6bn
Annual income statement for Kanaph Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 5,250 | 348 | 4,252 | 5,561 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 17,084 | 10,829 | 8,974 | 9,833 |
| Operating Profit | -11,834 | -10,480 | -4,723 | -4,273 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 3,820 | -12,586 | -28,271 | -35,560 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 3,820 | -12,586 | -28,271 | -35,560 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 3,820 | -12,586 | -28,271 | -35,560 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 3,820 | -12,586 | -28,271 | -35,560 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 295 | -971 | -2,182 | -2,744 |
| Dividends per Share |